Dianthus Therapeutics, Inc. (NASDAQ: DNTH) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT DIANTHUS THERAPEUTICS, INC.

Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
Listen to this Section


$80.10
-4.0300 ( -4.79% ) 378.8K

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Market Data


Open $80.10
Previous Close $84.13
Volume 378.8K
Market Cap $4.64B
Day Range $79.78 - $85.53
52 Week Range $16.64 - $96.50
Shares Outstanding 54.67M
Change % -4.79%
Net Change ▼ -4.0300
Insider Ownership -0.01%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2023
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -639,500.00

Date Type Amount Purchased Purchaser
2024-05-28 Sale -60000.00 CARR EDWARD
2024-05-28 Sale -75000.00 Veness Adam M
2024-05-28 Sale -100000.00 Randhawa Simrat
2024-05-28 Sale -100000.00 Savitz Ryan
2024-05-28 Sale -243000.00 Garcia Marino
2024-05-28 Sale -11000.00 Violin Jonathan
2024-05-28 Sale -11000.00 Soteropoulos Paula
2024-05-28 Sale -11000.00 MOULDER LEON O JR
2024-05-28 Sale -11000.00 McGeorge Anne
2024-05-28 Sale -11000.00 Lawton Alison Frances

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 75 Aug 07, 2025
8-k 8K-related 12 Aug 07, 2025

Latest News


× Before browsing our site, please accept our cookies policy